×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
27318894
2016
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
18676866
2008
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Multiple newly identified loci associated with prostate cancer susceptibility.
18264097
2008
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
The addition of a dual inhibitor of 5-a-reductase types 1 and 2 to antiandrogen therapy may further inhibit tumor growth, thus reducing the concentration of intracellular dihydrotestosterone, which is the primary androgen mediator of PSA gene expression in prostate tumor cell lines.
18500220
2008
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Differential regulation of clusterin and its isoforms by androgens in prostate cells.
17148459
2007
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.
17003774
2007
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
16442593
2006
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
16984552
2006
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
16424004
2006
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
Endocrine approaches in the therapy of prostate carcinoma.
15790600
2005
×
Entrez Id:
354
Gene Symbol:
KLK3
KLK3
Prostatic Neoplasms
0.400
Biomarker
CTD_human
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
12644816
2003